Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-CL-KYNA; AV101; L-4-chlorokynurenine; L-4-CL-KYN

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Artemis Neuroscience
  • Developer Baylor College of Medicine; National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Behavioural disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Neuropathic pain; Suicidal ideation
  • Preclinical Psychiatric disorders
  • No development reported Epilepsy; Huntington's disease; Parkinson's disease

Most Recent Events

  • 01 Nov 2019 VistaGen Therapeutics plans a phase II trial in Drug-induced dyskinesia and Parkinson's disease in July 2020 (PO) (NCT04147949)
  • 28 Oct 2019 VistaGen Therapeutics expands patent protection for AV 101 in Europe
  • 01 Oct 2019 VistaGen completes the phase II ELEVATE trial in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in USA (NCT03078322)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top